阿司匹林联合拉贝洛尔对妊娠期高血压患者血压、炎症因子、沉默信息调节因子的影响OA
Effects of Aspirin Combined with Labetalol on Blood Pressure,Inflammatory Factors and Silent Information Regulators in Patients with Hypertension in Pregnancy
目的:探讨75mg/d剂量阿司匹林联合拉贝洛尔对妊娠期高血压患者血压、炎症因子、沉默信息调节因子(SIRTs)的影响.方法:选取2022年3月～2023年3月期间于某院治疗的92例妊娠期高血压患者作为研究对象,采用随机数字表法分为对照组和观察组,每组46例.两组患者均给予镇静、扩容及限制盐摄入等常规治疗,对照组患者在常规治疗基础上加用盐酸拉贝洛尔片,观察组患者在对照组治疗基础上加用阿司匹林肠溶片.比较两组患者血压(收缩压、舒张压)、炎症因子[白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、白介素-8(IL-8)]、SIRTs[沉默信息调节因子1(SIRT1)、沉默信息调节因子3(SIRT3)]、不良妊娠结局及不良反应发生情况.结果:治疗后,两组患者舒张压、收缩压均降低(P<0.05),且观察组低于对照组(P<0.05);两组患者血清IL-6、TNF-α、IL-8水平均降低(P<0.05),且观察组低于对照组(P<0.05);两组患者血清SIRT1、SIRT3水平均升高(P<0.05),且观察组高于对照组(P<0.05).观察组患者不良妊娠结局发生率(21.74%)低于对照组(52.17%,P<0.05).两组患者不良反应发生情况比较无统计学差异(P>0.05).结论:75mg/d剂量阿司匹林联合拉贝洛尔治疗可有效控制妊娠期高血压患者血压,降低炎症因子水平,提高SIRT1、SIRT3水平,还可有效减少不良妊娠结局发生率,且不良反应发生率低.
Objective:To investigate the effects of 75mg/d aspirin combined with labetalol on blood pressure,inflammatory factors and silent information regulators(SIRTs)in patients with hypertension in pregnancy.Methods:A total of 92 hypertension in pregnancy patients treated in a hospital from March 2022 to March 2023 were selected and divided into the control group and observation group by random number table method,with 46 patients in each group.Both groups were given conventional treatment such as sedation,volume expansion and limiting salt intake.The control group was additionally treated with labetalol hydrochloride tablets,and the observation group was treated with aspirin enteric-coated tablets in addition to the treatment given in the control group.Blood pressures(systolic and diastolic blood pressures),inflammatory factors[interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),interleukin-8(IL-8)],SIRTs[silent information regulator 1(SIRT1),silent information regulator 3(SIRT3)],adverse pregnancy outcomes and adverse reactions were compared between the two groups.Results:After treatment,the diastolic and systolic blood pressures were decreased in both groups(P<0.05),and were lower in the observation group as compared with the control group(P<0.05).The serum levels of IL-6,TNF-α,IL-8 were decreased in both groups(P<0.05),and were lower in the observation group as compared with the control group(P<0.05).The serum levels of SIRT1 and SIRT3 were increased in both groups(P<0.05),and were higher in the observation group as compared with the control group(P<0.05).The incidence of adverse pregnancy outcomes in the observation group(21.74%)was lower than that in the control group(52.17%,P<0.05).No statistically significant difference in the occurrence of adverse reactions was observed between the two groups(P>0.05).Conclusion:75mg/d aspirin combined with labetalol in the treatment of hypertension in pregnancy can effectively control the blood pressure,reduce the levels of inflammatory factors,increase the levels of SIRT1 and SIRT3,and effectively reduce the incidence of adverse pregnancy outcomes with low incidence of adverse reactions.
李梦竹;李瓅;周亚丹
郑州市中心医院产科,郑州 450000
临床医学
阿司匹林拉贝洛尔妊娠期高血压炎症因子沉默信息调节因子
aspirinlabetalolhypertension in pregnancyinflammatory factorssilent information regulators
《中国合理用药探索》 2024 (006)
76-81 / 6
河南省医学科技攻关计划项目(LHGJ20210239)
评论